Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

NET LOSS PER SHARE (Details)

NET LOSS PER SHARE (Details)	3 Months Ended		6 Months Ended		128 Months Ended
NET LOSS PER SHARE (Details)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	36,782,459	24,339,800	36,782,459	24,339,800	36,782,459
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,291,638	4,827,638	6,291,638	4,827,638	6,291,638

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References + Details